London, 07 August 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Intranasal Drug Delivery Market 2014-2018, which is expected to grow at a CAGR of 2.92 percent during the period 2013-2018.
Intranasal drug delivery is used to treat local diseases in the nose and paranasal sinus such as allergic and non-allergic rhinitis and sinusitis.. These systems provide an easy mode of administration for patients on long-term therapy, avoid risk of overdose, and enhance the bioavailability of the drug.
Key Market Drivers
- Increase in Aging Population
- Development in Applications
- Increase in Incidence of Allergic Rhinitis
Key Market Trends
- Increased Adoption of Non-invasive Products
- Growing Demand for Self-administered Products
- Increase in Online Marketing Services
“Self-administration intranasal drug delivery systems could save time and cost in mass vaccination settings,” says Faisal Ghaus, Vice President of TechNavio.
“Scientists are developing new formulations to deliver a protein and peptide compound because of growing demand for nasal self-administrating products.”
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
